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in 1996,[4] the identiﬁ  cation of mutations and investigation 
of genotype-phenotype relationships of channelopathies 
have become focal points in the ﬁ  eld of genetics and 
cardiology. For Brugada syndrome alone, 7 related 
genes, and hundreds of associated mutations have been 
identiﬁ  ed.[5,6] SCN5A, encoding the Nav1.5 α-subunit, 
causes the sodium ion channel “loss-of-function”;[7] 
GPD1L, encoding glycerol-3-phosphate dehydrogenase-1 
like protein, and whose mutations interact with sodium 
channel α-subunit, also leads to sodium channel “loss-of-
function”;[8] CACNA1C, encoding the Cav1.2 α-subunit, 
gives rise to calcium channel “loss-of-function”;[9] 
CACNB2, encoding the Cav1.2 β-subunit, results in 
calcium channel “loss-of-function”;[9] SCN1B, encoding 
the Nav1.5 β-subunit, induces sodium channel “loss-of-
function”;[10] SCN3B, encoding Nav1.5 β-subunit, induces 
sodium channel “loss-of-function”;[11] KCNE3, encoding 
the β-subunit of several potassium channels, including 
Kv4.3, which conducts transient outward potassium 
current (Ito), brings on “gain-of-function” of slowly 
activated delayed rectiﬁ  er potassium current (Iks) and 
Ito.[11] Mutations in SCN5A account for roughly 20%-30% 
of all cases of Brugada syndrome while mutations in 
the other 6 genes account for only a very small number 
of Brugada syndrome phenotypes. The remaining 70%-
80% of patients who meet the clinical diagnosis criterion 
do not harbor any of the associated mutations.[6]
Interestingly, almost all mutations lead to “loss-of-
function” in sodium channels or calcium channels, 
except for KCNE3, whose mutation gives rise to 
potassium channel “gain-of-function”.[12]
Cardiac channelopathy, or primary cardiac electrical disease 
indicates myocyte ion channel dysfunction due to encoding 
ion channel gene and related gene mutation. Channelopathy 
usually causes the unstable cardiac electrical activity and 
results in arrhythmia. Brugada syndrome, long QT syndrome 
and short QT syndrome are three paradigms of congenital 
cardiac channelopathies in which a single gene mutation causes 
clinical arrhythmia, syncope and sudden cardiac death (SCD). 
They are currently the best available channelopathy models 
for evaluating the relationship between genotype-phenotype 
and understanding the electrophysiological mechanisms for 
malignant arrhythmia. They also represent bridges between 
modern molecular biology and clinical cardiology. However, 
there are incomplete penetrance and substantial heterogeneity 
in genotype-phenotype relationships, resulting in a very 
broad clinical disease spectrum for each channelopathy. 
This heterogeneity can be manifested as carriers of silent 
gene mutations, different responses to drug challenge tests, 
asymptomatic individuals with spontaneous electrocardiogram 
(ECG) abnormalities, iterative syncope patients, and aborted 
SCD patients to SCD victims.[1,2] Identiﬁ  cation of all disease-
causing genes and the associated mutations will improve 
pre-symptomatic diagnosis and enable early intervention and 
follow-up of asymptomatic patients, although clinical data 
presently available show that genetic testing results cannot 
be used for prognostic forecast and risk stratiﬁ  cation for 
Brugada syndrome.[3]
DISCOVERY OF CAUSATIVE GENE MUTATIONS 
Since Wang et al, reported genomic organization of the 
human SCN5A gene encoding the cardiac sodium channel 
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Other exciting discoveries in the channelopathy field 
are (1) from silent mutant gene carriers to SCD, one 
mutation can cause distinct phenotypes; (2) different 
mutations of one mutant gene can result in various types 
of channelopathies; and (3) the combination of different 
mutations can lead to mixed phenotypes or “overlap 
syndrome”. For example, SCN5A gene, if its mutation 
gives rise to sodium channel “loss-of-function”, results in 
Brugada syndrome, family progressive cardiac conduction 
disease and sick sinus syndrome; if its allele mutations lead 
to sodium channel “delayed inactivation”, it causes long 
QT syndrome type 3 (LQT3) clinical phenotype. Moreover, 
SCN5A mutant gene is also responsible for dilated 
cardiomyopathy, atrial ﬁ  brillation, and sudden infant death 
syndrome.[5,13] If more than one mutations of SCN5A co-
exist, mixed or “overlap syndrome” clinical phenotypes may 
occur.[13] Hence, identifying causative genes and 
understanding the basis for ion channel functional 
abnormalities as well as the genotype-phenotype 
relationship is critical for explaining clinical phenomena 
and formulating appropriate therapeutic strategies. 
Clinically, Brugada syndrome and LQT3 possess distinct 
ECG phenotypes: right precordial ECG leads to V1 to 
V3 ST segment elevation for Brugada syndrome while 
QT interval prolongation for LQT3. However, these 2 
clinical entities share some common clinical characteristics 
and presentations: including predominance in males; 
deadly arrhythmia events occurring more frequently at 
night or at rest; and no beneﬁ  t or even harmful effect of 
β-blocker medication has. Therefore, in the viewpoint 
of the mutation, ion channel functional abnormality and 
genotype-phenotype relationship, we can ﬁ  nd that all these 
phenomena are reasonable and β-blocker should be avoided 
for these patients.
The exciting achievements in research noted above have 
greatly enriched our knowledge of the electrophysiological 
basis of malignant arrhythmia. However, some signiﬁ  cant 
problems have arisen in the ﬁ  eld of channelopathy, as will 
be discussed below.
WHAT ARE THE REMAINING CAUSES OF DISEASE 
FOR CHANNELOPATHY PATIENTS?
As noted above, among all of the Brugada syndrome 
causative genes, SCN5A, which includes hundreds of 
associated mutations, accounts for about 20%-30% of the 
Brugada syndrome clinical phenotypes, while mutations in 
the other 6 recently identiﬁ  ed related mutant genes only 
account for one family or a very small number of Brugada 
syndrome phenotypes. What are the causes for the disease 
in the remaining 70%-80% of all patients? This is still a 
conundrum and a big challenge for researchers.[3,14]
DEEP DILEMMA FOR INTERPRETATION 
OF THE GENETIC TESTING RESULTS OF 
CHANNELOPATHY
For asymptomatic long QT syndrome, Brugada syndrome 
and short QT syndrome patient family members, silent 
mutant gene carriers, positive drug challenge test patients 
and asymptomatic individuals with spontaneous ECG 
abnormality, accurate diagnosis is of critical importance. 
Theoretically, genetic testing is the “gold standard” to 
determine the preventive and follow-up plan, therapeutic 
strategy and prognostic estimation for these patients. 
However, for example Brugada syndrome, restricted by 
limited clinical and genetic data, cardiologists are usually 
confronted with the following challenges: (1) for 70%-80% 
of Brugada syndrome patients, the genetic test results are 
negative;[6] (2) even if the genetic test results are positive, 
the mutations may be harmless nonsense mutations;[14] 3) 
mutations may be harbored in all of us. For example, the 
SCN5A mutant gene is mutated in 2-5% of “normal” 
individuals although the associated mutations of Brugada 
syndrome are usually found in the seven transmembrane 
domains and pore-forming segments while the mutations 
of “normal” individuals are often located in linking 
areas;[6,14] (4) for most Brugada syndrome patients with 
identiﬁ  ed mutations, the mutations are usually “private”,[6] 
so it’s impossible to use mutant function studies for every 
patient; (5) the in vitro mutant function study results may 
be different from the pathophysiological condition in 
vivo.[14] Practically, these are the toughest conundrums 
to cardiologists. Once the channelopathy diagnoses are 
established, patients and their families would endure 
tremendous psychological and social suffering; conversely, 
if diagnoses are overlooked, each arrhythmic event could be 
deadly. Faced with relatively young individuals who could 
be at risk, which course of action is appropriate for the 
cardiologist? This is a deep dilemma indeed.
DRUG-INDUCED CHANNELOPATHIES
Some drug-induced channelopathies also represent a 
clinical dilemma.[15,16] First, little is known about whether 
there is existence of proarrhythmic substrates in the 
population with drug-induced channelopathies such as 
Brugada syndrome, due to limited randomized, double-
blinded, controlled, long-term follow-up data and genetic 
data from international multi-center collaborative clinical 
trials. Second, it is not clear whether these patients always lie 
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in cardio-electrical stable condition, and if there is a genetic 
predisposition in these patients. Fortunately, 10%-15% of 
drug-induced QT-prolongation individuals who developed 
tosades de points (TdP) possess mutations associated with long 
QT syndrome.[17] This result perhaps provides us with an 
important clue to handle the population of drug-induced 
Brugada-like ECG patterns.
Therefore, in the future, answers to overcome these 
problems raised above will probably rely on: (1) randomized, 
controlled, international multi-center collaborative clinical 
trials, and long-term follow-up accumulative data; (2) 
identiﬁ  cation of more disease-causing genes and mutant 
sites, as well as reinforcement of mutant function studies 
for enhancement of our genetic database incessantly.
In this issue, Dr. Liang et al. report 2 novel mutations in 
the SCN5A gene. 1 of the mutations is associated with 
Brugada syndrome and the other with LQT3, based on 
genetic analysis of 4 diagnosed and 9 suspected Brugada 
syndrome patients and 3 LQT3 Chinese patients. 
These results enrich the channelopathy genetic database 
although further mutation-function studies are necessary 
to conﬁ  rm the physiological relevance of these ﬁ  ndings.
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